HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
JM 335
JM149 is the cis congener of JM335; structure given in first source
Also Known As:
JM 149; JM-335; JM149; JM335; cis,trans,cis-(PtCl2(OH)2(c-C6H11NH2)(NH3)); trans-ammine(cyclohexylamine)dichlorodihydroxo-platinum(IV)
Networked:
6
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Organometallic Compounds: 64
Organoplatinum Compounds
JM 335: 6
Related Diseases
1.
Carcinoma (Carcinomatosis)
11/01/1994 - "
In vitro, against 5 human ovarian carcinoma cell lines, JM335 was comparably cytotoxic to cisplatin itself and over 50-fold more potent than transplatin (mean 50% inhibitory concentrations: JM335, 3.1 microM; cisplatin, 4.1 microM; transplatin, 162 microM).
"
11/01/1994 - "
In vivo, JM335 produced growth delays in excess of 15 days against 4 of 6 human ovarian carcinoma xenografts and was unique among the complexes studied in retaining some efficacy against a cisplatin-resistant subline of the murine ADJ/PC6 plasmacytoma.
"
10/01/1994 - "
Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
"
09/15/1995 - "
We have investigated the comparative initial DNA binding properties of 7 platinum-based anticancer drugs: 5 cis-oriented compounds, cisplatin, tetraplatin (Ormaplatin), JM118 [cis ammine dichloro (cyclohexylamine) platinum (II)], JM216 [bisacetato cis ammine dichloro (cyclohexylamine) platinum (IV)] and JM149 [cis ammine dichloro (cyclohexylamine) trans dihydroxo platinum (IV)], and 2 trans-oriented compounds, transplatin and JM335 [trans ammine dichloro (cyclohexylamine) dihydroxo platinum (IV)] in SKOV-3 and CHI human ovarian carcinoma cells.
"
2.
Plasmacytoma
11/01/1994 - "
In vivo, JM335 produced growth delays in excess of 15 days against 4 of 6 human ovarian carcinoma xenografts and was unique among the complexes studied in retaining some efficacy against a cisplatin-resistant subline of the murine ADJ/PC6 plasmacytoma.
"
01/01/1996 - "
Two pairs of cis/trans platinum complexes, JM118 (cis-ammine(cyclohexylamine) dichloro platinum(II)) and its trans counterpart, JM334 and JM149 (cis-ammine(cyclohexylamine) dichloro-dihydroxo platinum(IV)) and its trans counterpart JM335 have been evaluated (both in vitro and in vivo) against two murine tumour models of historical importance in the discovery of novel platinum drugs; the ADJ/PC6 plasmacytoma and the L1210 leukaemia and sublines selected for resistance to platinum drugs.
"
3.
Neoplasms (Cancer)
07/01/1995 - "
Together with the trans-platinum complex JM335, it provides new chemical guidelines for the development of compounds that may circumvent cisplatin resistance in tumors.
"
4.
Hypersensitivity (Allergy)
07/01/1998 - "
None of the mutants demonstrated appreciable change in sensitivity to JM216 presumably as a consequence of a lack of resistance of the wild-type strain, whereas a moderate increase in sensitivity to JM335 was observed for most of the mutants, and hypersensitivity to BBR3464 was observed only in rad1 and -3. No relevant changes in sensitivity to tetraplatin were observed.
"
Related Drugs and Biologics
1.
Cisplatin (Platino)
2.
PC6 extract (PC6)
3.
Platinum
4.
JM 335
5.
Cyclohexylamines
6.
ormaplatin
7.
amminedichloro(cyclohexylamine)platinum(II)
8.
satraplatin (JM 216)
9.
transplatin
10.
DNA (Deoxyribonucleic Acid)